Publications by authors named "Verity Saunders"

Claim this Profile
I
Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations.
Naranie Shanmuganathan, David T Yeung, Carol Wadham, Adelina Fernandes, Muneeza Maqsood, Verity Saunders

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced Detection of Splice-Altering Variants in Hematologic Malignancies Using Targeted RNA-Sequencing Data.
Muneeza Maqsood, John Toubia, Carol Wadham, Naranie Shanmuganathan, Nur Hezrin Shahrin, Verity Saunders

J Mol Diagn· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib.
Chung Hoow Kok, Yazad Irani, Jade Clarson, Verity Saunders, Phuong Dang

Blood Neoplasia· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy.
Ilaria S Pagani, Naranie Shanmuganathan, Phuong Dang, Verity A Saunders, Randall Grose

Blood· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention.
Naranie Shanmuganathan, Carol Wadham, NurHezrin Shahrin, Jinghua Feng, Daniel Thomson, Verity Saunders

Haematologica· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib.
Chung H Kok, Verity A Saunders, Phuong Dang, Naranie Shanmuganathan, Deborah White

Blood Cancer J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines.
Monika M Kutyna, Sophie Loone, Verity A Saunders, Deborah L White, Chung H Kok

Int J Mol Sci· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission.
Liu Lu, Chung Hoow Kok, Phuong Dang, Susan Branford, Verity A Saunders

Br J Haematol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia.
Naranie Shanmuganathan, Carol Wadham, Daniel Thomson, Nur Hezrin Shahrin, Chloe Vignaud, Verity Saunders

J Mol Diagn· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simvastatin enhances the efficacy of nilotinib in chronic myeloid leukaemia by post-translational modification and drug transporter modulation.
Kartini Asari, Wen Tian Sun, Ze Hui Kok, Yi Hui Lam, Bee Ling Ng, Verity Saunders

Anticancer Drugs· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients.
Ulf Schmitz, Jaynish S Shah, Bijay P Dhungel, Geoffray Monteuuis, Phuc-Loi Luu, Verity A Saunders

Cancers (Basel)· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 transcripts in chronic myeloid leukemia.
Ilaria S Pagani, Phuong Dang, Verity A Saunders, Jodi Braley, Angelica Thieleke

Leuk Lymphoma· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission.
Ilaria S Pagani, Phuong Dang, Verity A Saunders, Randall Grose, Naranie Shanmuganathan

Leukemia· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia.
David M Ross, Ilaria S Pagani, Yazad D Irani, Jade Clarson, Tamara Leclercq, Verity A Saunders

Br J Haematol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib.
Chung H Kok, David T Yeung, Liu Lu, Dale B Watkins, Tamara M Leclercq, Verity A Saunders

Blood Adv· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia.
Ilaria S Pagani, Phuong Dang, Ivar O Kommers, Jarrad M Goyne, Mario Nicola, Verity A Saunders

Haematologica· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
David M Ross, Ilaria S Pagani, Naranie Shanmuganathan, Chung H Kok, John F Seymour, Verity A Saunders

Leukemia· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant + cell lines.
Liu Lu, Chung Hoow Kok, Verity Ann Saunders, Jueqiong Wang, Jennifer Anne McLean

Oncotarget· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression .
Laura N Eadie, Verity A Saunders, Susan Branford, Deborah L White, Timothy P Hughes

Oncotarget· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia.
Ilaria S Pagani, Chung H Kok, Verity A Saunders, Mark B Van der Hoek, Susan L Heatley

J Mol Diagn· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.
Jueqiong Wang, Liu Lu, Chung H Kok, Verity A Saunders, Jarrad M Goyne

Haematologica· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells.
Devendra K Hiwase, Verity A Saunders, Eva Nievergall, Douglas D Ross, Deborah L White

Haematologica· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.
Laura N Eadie, Verity A Saunders, Timothy P Hughes, Deborah L White

Leuk Lymphoma· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.
Deborah L White, Jerald Radich, Simona Soverini, Verity A Saunders, Amity K Frede

Haematologica· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells.
Jane R Engler, Amity Frede, Verity Saunders, Andrew Zannettino, Deborah L White

Blood· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis